Sign Out
Multiple Myeloma and Bone Metastasis from Solid Tumors: Denosumab (XGEVA) is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.
Giant Cell Tumor of Bone: Denosumab (XGEVA) is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity [see Pharmacology: Pharmacodynamics: Clinical Trials: Multiple Myeloma under Actions].
Hypercalcemia of Malignancy: Denosumab (XGEVA) is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.
Continue with Google